Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Search Results for "Rituximab Patent"

10:43 EDT 21st April 2014 | BioPortfolio

Matching Channels

CD20 Antibodies

The chimeric anti-CD20 antibody rituximab (Rituxan & MabThera) from Biogen Idec and Genentech/Roche is one of the world’s commercially most successful antibodies (2007 sales of over US$ 5 bl...

Biosuperior Antibodies

After biosimilar versions of therapeutic proteins have become reality in Europe and in the US, now it’s the turn of therapeutic antibodies to be in the line of fire. Patents of the first wave of...

India

India, in the Asian subcontinent is the world’s fourth largest producer of pharmaceuticals, and is thought as one of the most promising biotech markets in the world. Several important steps...

Drug Delivery - news, views, blogs

Drug delivery is the method or process of administering a pharmaceutical compound to achieve a therapeutic effect in humans or animals.  Drug delivery technologies are patent protected formulat...

Tumor Necrosis Factor TNF Products

Tumor Necrosis Factor (TNF) and TNF receptor antagonists and agonists used to treat TNF-mediated inflammatory diseases such as rheumatoid arthritis or to treat cancer. TNF blockers are the commerc...

Matching News

Combination of Idelalisib and Rituximab Improves Survival in Patients with Relapsed Chronic Lymphocytic Leukemia

In an international randomized double-blind phase III clinical trial, patients with relapsed chronic lymphocytic leukemia (CLL) who received the investigational drug idelalisib in combination with rit...

[Comment] Subcutaneous rituximab: a practical approach?

Rituximab, a chimeric anti-CD20 monoclonal antibody, has improved the therapeutic outcomes of patients with B-cell non-Hodgkin lymphoma of various histopathological subtypes and B-cell chronic lymphoc...

Additional rituximab dose can improve response to treatment in rheumatoid arthritis

People with rheumatoid arthritis who are treated with rituximab could sometimes benefit from an extra dose of the drug if they seem to be responding poorly, says research published in the Annals of th...

[Articles] Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study

Stage 1 data show that the pharmacokinetic profile of subcutaneous rituximab was non-inferior to intravenous rituximab and was not associated with new safety concerns. Stage 2 will provide data for ef...

Phase 1 study shows equivalence of biosimilar rituximab and MabThera

The results of a randomized, controlled, multicentre, two-arm, parallel-group, double-blind study of CT-P10 (rituximab) in patients with rheumatoid arthritis has shown the equivalence, with respect to...

Subcutaneous Rituximab Recommended in the EU

A positive opinion from the Committee for Medicinal Products for Human Use means that the subcutaneous formulation of rituximab might soon be available in the European Union (EU). International Appr...

[News] 55th ASH Annual Meeting

Treatment with idelalisib plus rituximab increased overall survival compared with rituximab alone in patients with chronic lymphocytic leukaemia (CLL), according to findings from a phase 3 trial. In t...

ASH 2013: Final stage II results of the CLL11 trial

A commonly used combination treatment for CLL consists of chemotherapy and rituximab, a synthetic molecule engineered to target a protein on the surface of CLL cells (CD20). While effective, rituxima...

Matching PubMed Articles

Patent highlights.

A snapshot of recent key developments in the patent literature of relevance to the advancement of pharmaceutical and medical R&D.

Patent quality.

Against a backdrop of a rising generics market and increasing patent expiries, the 'quality' of patents has become an ever more significant topic of debate. Pharmaceutical Patent Analyst has brought t...

Patenting time-lapse microscopy: the European story.

European Patent No. 2430454 of Stanford University is open to opposition before the European Patent Office if such opposition is filed by 23 October 2013. This is the European equivalent of the US Pat...

Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy.

To evaluate the efficacy and safety of two different targeted approaches-abatacept or tocilizumab-after rituximab therapy in rheumatoid arthritis, and to explain observed difference in efficacy using...

Fc γ -Receptor IIIA Polymorphism p.158F Has No Negative Predictive Impact on Rituximab Therapy with and without Sequential Chemotherapy in CD20-Positive Posttransplant Lymphoproliferative Disorder.

We retrospectively analyzed the p.V158F polymorphism of Fc γ -receptor IIIA (FCGR3A, CD16) in patients with PTLD treated with rituximab monotherapy. Previous reports had indicated that the lower affi...

Search Whole site using Google

Loading
Search BioPortfolio:
Advertisement
Advertisement
Advertisement Advertisement